1,689 research outputs found
Pontoppidan og rabbinerens datter
No full textAbstractIn 1918, Henrik Pontontoppidan published a small text based on a holiday memoir. It is called The Priest´s Daugther and is about a young orthodox Jewish girl, who wants to spend her summer holiday at a seaside hotel in Blokhus, Denmark. It is not a success, she does not fit in and has to go back to her family before time. In this article, Henrik Loft Nielsen traces the story back to the summer of 1887, when Pontoppidan spent a prolonged holiday in Blokhus at the same time as a young Jewish girl from his native town, Randers. Loft Nielsen tells the girl´s story up to its sad ending in 1891.
On this holiday, Pontoppidan also met another young woman, AntoinetteKofoed, who was to become his second wife later. She too plays a part in the story.
In 1930 the short story was republished in a rewritten form and with the title The Rabbi´s Daugther
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment
No full textBackground Analysis of efficacy and tolerability of vortioxetine 20 mg/day, and optimal timing of dose adjustment, in patients with major depressive disorder (MDD). Methods Pooled analysis of six randomized, fixed-dose studies of vortioxetine 5 to 20 mg/day. Mean change from baseline in Montgomery-angstrom sberg Depression Rating Scale (MADRS) total score was analyzed by vortioxetine dose using a mixed model for repeated measures. Tolerability was assessed over the 8-week treatment period and from day 8 (ie, following dose increase to 20 mg/day). Data from three randomized, flexible-dose studies were examined for frequency and timing of dose adjustment. Results A clear dose-response relationship for vortioxetine was confirmed in terms of improvement in MADRS total score. Significant differences vs placebo were seen for vortioxetine 20 mg/day from week 2 onwards; vortioxetine 10 mg did not separate from placebo until week 4. At week 8, mean change in MADRS total score from baseline was significantly greater for vortioxetine 20 mg/day vs 10 mg/day (difference, -1.03 points; P < .05). Incidence of adverse events was not increased in patients who received vortioxetine 20 mg/day vs 10 mg/day. In flexible-dose studies, dosage was increased to 20 mg/day after 1 week in 48.0% of patients; final dosage was 20 mg/day in 64.3% of patients. Conclusions Vortioxetine 20 mg is significantly more effective than vortioxetine 10 mg in patients with MDD, with a similar tolerability profile. In flexible-dose studies, almost half of all patients received 20 mg/day after 1 week and two-thirds received 20 mg/day as their final dosage. © The Author(s), 2021. Published by Cambridge University Pres
Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
No full textBackground: Vortioxetine has demonstrated dose-dependent efficacy in patients with major depressive disorder (MDD), with the greatest effect observed with vortioxetine 20 mg/day. This analysis further explored the clinical relevance of the more rapid and greater improvement in depressive symptoms observed with vortioxetine 20 mg/day vs 10 mg/day. Methods: Analysis of pooled data from six short-term (8-week), randomized, placebo-controlled, fixed-dose studies of vortioxetine 20 mg/day in patients with MDD (N = 2620). Symptomatic response (≥50% decrease in Montgomery-Åsberg Depression Rating Scale [MADRS] total score), sustained symptomatic response, and remission (MADRS total score ≤10) were assessed by vortioxetine dosage (20 or 10 mg/day). Results: After 8 weeks, 51.4% of patients receiving vortioxetine 20 mg/day had achieved symptomatic response vs 46.0% of those receiving vortioxetine 10 mg/day (P < .05). Significantly more patients achieved symptomatic response vs placebo from week 2 onwards for vortioxetine 20 mg/day and from week 6 onwards for vortioxetine 10 mg/day (both P ≤ .05). Sustained response was achieved from week 4 for 26.0% of patients receiving vortioxetine 20 mg/day vs 19.1% of those receiving vortioxetine 10 mg/day (P < .01), increasing to 36.0% and 29.8%, respectively, over the 8-week treatment period (P < .05). At week 8, 32.0% of patients receiving vortioxetine 20 mg/day were in remission vs 28.2% of those receiving vortioxetine 10 mg/day (P = .09). Rates of adverse events and treatment withdrawal were not increased during the week following vortioxetine dose up-titration to 20 mg/day. Conclusion: Vortioxetine 20 mg/day provides more rapid and more sustained symptomatic response than vortioxetine 10 mg/day in patients with MDD, without compromising tolerability
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability
No full textBackground: Patients with major depressive disorder (MDD) often experience comorbid anxiety symptoms. Vortioxetine has demonstrated efficacy in treating anxiety symptoms in patients with MDD; however, efficacy and tolerability have not been assessed across the entire approved dosage range. Methods: The efficacy and tolerability of vortioxetine 5-20 mg/day were assessed in patients with MDD and high levels of anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] total score ≥ 20) using pooled data from four randomized, fixed-dose, placebo-controlled studies (n = 842). Data from a randomized, double-blind study of vortioxetine 10-20 mg/day versus agomelatine 25-50 mg/day in patients with an inadequate response to prior therapy (n = 299) were analyzed separately. Mean changes from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), HAM-A, and Sheehan Disability Scale (SDS) total scores were analyzed by vortioxetine dosage. Results: The pooled analysis of fixed-dose studies demonstrated a clear dose-response relationship for vortioxetine 5-20 mg/day for improvements in MADRS, HAM-A, and SDS total scores. Vortioxetine 20 mg/day demonstrated significant effects versus placebo from week 4 onwards. In the post hoc analysis of the active-controlled study in patients with inadequate response to prior therapy, vortioxetine 10-20 mg/day was superior to agomelatine across all outcome measures from week 4 onwards. Up-titration of vortioxetine to 20 mg/day was not associated with an increase in adverse events. Limitations: Short-term trials. Conclusions: Vortioxetine is efficacious and well tolerated in patients with MDD and high levels of anxiety symptoms, including those with an inadequate response to prior therapy. The greatest therapeutic benefits were observed with vortioxetine 20 mg/day. Trial registration: NCT01140906, NCT01153009, NCT01163266, NCT01255787, NCT01488071
Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting
No full textBackground
The Oxford Depression Questionnaire (ODQ) is a patient-reported scale for assessing emotional blunting in patients with major depressive disorder (MDD). This analysis was undertaken to further validate the scale in patients experiencing emotional blunting while receiving antidepressant treatment.
Methods
Patients with MDD who experienced inadequate depressive-symptom resolution and emotional blunting on selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor monotherapy (adequate dose for ≥6 weeks) were switched to vortioxetine 10–20 mg/day. ODQ total scores were assessed excluding and including the “antidepressant-as-cause” domain (ODQ-20 and ODQ-26, respectively). Anchor- and distribution-based methods were used to determine the minimal clinically important difference in ODQ scores in terms of change from baseline to week 8 of antidepressant treatment.
Results
After 8 weeks of vortioxetine treatment, the mean change in ODQ-20 and ODQ-26 scores from baseline was −24.8 and −30.1 points, respectively. Greater mean changes from baseline in ODQ-20 and ODQ-26 scores were seen in patients reporting no emotional blunting vs those still experiencing emotional blunting after 8 weeks of vortioxetine treatment (ODQ-20: −27.0 vs −22.6 points; ODQ-26: –32.8 vs –27.5 points, respectively). In patients considered clinically minimally improved (Clinical Global Impression–Improvement score, 3) after 8 weeks of vortioxetine treatment, respective mean (standard deviation) change in ODQ-20 and ODQ-26 score from baseline was −15.5 (18.1) and –20.0 (20.5) points.
Limitations
Short study duration.
Conclusions
These results provide further validation of the clinical utility of the ODQ for assessing emotional blunting in patients with MDD. The suggested minimal clinically important difference for change in ODQ-20 and ODQ-26 scores is 16 and 20 points, respectively, after 8 weeks of antidepressant treatment.
Trial registration
ClinicalTrials.gov identifier: NCT03835715
Report on the Historic Ventilation system of the Palace of Westminster's River Front
No full textReport submitted to the Parliamentary Estate Division on 12 April 2014. It is based on extensive archival research undertaken by Dr. Henrik Schoenefeldt outline the design and development of the ventilation of the Houses of Parliament. The focus on the ventilation of the River Front, including the Committee Rooms. It includes historic plans, details, new drawings produced by the author to reconstruct the historic ventilation system
Henrik Pontoppidans "Märchen"
No full textDer dänische Nobelpreisträger Henrik Pontoppidan (1857-1943) ist vor allem für seine drei großen Romane "Det forjættede Land", "Lykke-Per" und "De Dødes Rige". Von großer Bedeutung sind aber auch seine Erzählungen, die vom landlichen Leben und den sozialen Unterschieden geprägt sind. Die Märchensammlung "Krøniker" erschien im Jahr 1890 und enthält verschiedene fürr Pontoppidans Schaffen signifikante Merkmale. In der vorliegenden Arbeit werden diese vorgestellt. Der Hauptteil stellt die Übersetzung von "Krøniker" ins Deutsche dar.The danish nobel prize winner Henrik Pontoppidan (1857-1943) is known for the novels "Det forjættede Land", "Lykke-Per" und "De Dødes Rige". His tales, in which Pontoppidan described the daily life of poor farmers and rich lairds, are as well of importance. The fairytalecollection "Krøniker" was published in 1890 and presents some significant characteristics of the author. These characteristics are explained in this thesis. The mainpart is the translation of "Krøniker"
Reflections on an international engagement in the fight against torture
No full textContribution to the 30th Anniversary of the Torture Journal by Henrik Døcker. The author describes some of the early beginnings of the RCT and Torture Journal
First Report on the Victorian ventilation system of the House of Lords: Its design and evolution 1839-54
No full textReport submitted to the Parliamentary Estate Division on 9 January 2014. It is based on extensive archival research undertaken by Dr. Henrik Schoenefeldt between November 2011 and December 2014 and outlines the design of the House of Lords' historic stack ventilation system. It also explores its evolution over the period between 1839-54. It comprises of two volumes: Volume I: Written Report, Volume II: Catalogue of drawings, including historic plans and details as well as new drawings produced by the author to reconstruct the historic system
Methods in epidemiologic research
No full text"This book started life as a veterinary text: Veterinary Epidemiologic Research. ... Methods in Epidemiologic Research is based heavily on the material covered in Veterinary Epidemiologic Research, with 2 major changes. Firstly, all of the veterinary examples have been replaced with human medical examples. ... Secondly, nearly all references have been switched from veterinary to human examples and references have been updated (particularly for the chapters dealing with study design). It is our sincere hope that we have produced a text that will serve the medical epidemiological community as well as our first text has served the veterinary community."--Preface, p. xviii.Ian Dohoo, Wayne Martin, Henrik Stryhn.; :ill. ;25 cm; Includes bibligraphical references and index.; Two of the authors, Ian Dohoo and Henrik Stryhn, are members of faculty at the University of Prince Edward Island.Source type: Print(0
- …
